

REFERENCES

- Ahren B, Gomis R, Standi E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2004;27(12):2874-2880.
- Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related p-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. *Diabetes Care* 2005; 28: 1936-1940.
- Allen E, Hollander P, Li J, Chen R. Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes. 44th Annual Meeting of the European Association for the Study of Diabetes. Rome, Italy, 7-11 September 2008.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2011 Jan;34 Suppl LS62-9.
- Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. *J Clin Invest* 2005; 115: 2047-58.
- Baggio, LL and Drucker, DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology* 2007; 132(6): 2131-2157.
- Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. *Curr Med Res Opin* 2007; 23: 1493-507.
- Best JH, Hoogwerf BJ, Herman WH, Peiletier EM, Smith DB, Wenten M, Hussein MA. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-

lowering therapies: a retrospective analysis of the LifeLink database. *Diabetes Care*. 2011 Jan;34(1):90-5.

- Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. *Diabetes Obes Metabol* 2009; 11(Suppl.3): 26-34.
- Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. *Diabetes Care* 2004; 27: 1660-7.
- Bristol-Myers Squibb. Onglyza [Summary of Product Characteristics] . Middlesex, England: Bristol-Myers Squibb /AstraZeneca EEIG, 2009. Available from URL: http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed 30 AprH 2010.
- Brubaker PL, Drucker DJ (2004) Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. *Endocrinology* 145:2653-2659
- Bunck MC, Eliasson B, Corner A, Heine RJ, Shaginian RM, Taskinen MR, Yki-Jarvinen H, Smith U, Diamant M. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. *Diabetes Obes Metab*. 2010 Dec 22. doi: 10.1111/j.1463-1326.2010.01355.x.
- Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004; 27: 2628-2635.
- Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD.

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004; 27: 2628-2635.

- Buse JB, Rosenstock J, Sesti G et al. & LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet* 2009; 374: 39—47.
- Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009;374(9683):39-47.
- Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009;374(9683):39-47.
- Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. *Aliment Pharmacol Ther* 2001; 15: 137-42.
- Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. *J Am Pharm Assoc*. 2009 Sep-Oct;49 Suppl 1:S3-9.
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. *Can J Diabetes* 2008; 32(Suppl.1): S1-201.
- Cavaghan M, Ehrmann D, Polonsky K. Interactions between insulin resistance and insulin secretion in the development of glucose

intolerance. J Clin Invest 2000; 106: 329-333.

- Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, QV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395-1406.
- Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R, CV181-040 Investigators. Saxagliptin added to a submaximal dose* of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395-1406.
- Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits p-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006; 346: 1067-1074.
- Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-94.
- Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin 2007; 23: 905-17.
- Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003; 26: 1847-51.
- Colca JR, Kletzien RF. What has prevented the expansion of insulin sensitisers? Expert Opin Investig Drugs 2006; 15: 205-10.
- Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz

O, Verhoeven R, Buganova I, Madsbad S (2008) Beneficial effects of once-daily liraglutide, a human glucagonlike peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. *Diabet Med* 25:1129-1131

- DeFronzo RA, Hissa MN, Garber AJ et al. & Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care* 2009; 32: 1649— 1655.
- DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. *Curr Med Res Opin* 2008; 24: 2943-2952. j> DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2005;28(5): 1092-1100.
- DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005; 28: 1092-1100.
- DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005; 28: 1092-1100.
- Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

Curr Med Res Opin 2009; 25: 1019-1027.

- DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
- Drucker DJ, Buse JB, Taylor K et al. & DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
- Drucker DJ, Buse JB, Taylor K et al. & DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
- Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
- Drucker DJ. Glucagon-Like Peptide-1 and the Islet β -Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. Endocrinology 2003; 144(12): 5145-5148.
- Emamaullee JA, Merani S, Toso C et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 2009; 150: 2145-2152.
- European Medicines Agency. Victoza (liraglutide) product

information. 2009. Available from URL: <http://www.emea.europa.eu/humandocs/PDFs/EPAR/victoza/H-1026-PI-en.pdf>. Accessed 30 April 2010.

- Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, Li WI, MacConell L. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. *Clin Pharmacokinet*. 2011 Jan 1;50(1):65-74.
- Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. *Horm Metab Res* 2009; 41: 905-909.
- Fonseca V, Madsbad S, Falahati A, Zychma M, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic BP—a meta-analysis of 6 clinical trials. Program and abstracts of the American Diabetes Association (ADA) 69th Scientific Sessions. New Orleans, Louisiana, 5-9 June 2009.
- Froguel P, Velho G. Genetic determinants of T2DM. *Recent Prog Horm Res* 2001; 56: 91-105.
- Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over. *Int J Clin Pract* 2010; 64: 267-276.
- Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. *Drug Saf* 2010; 33: 87-100.
- Garber A, Henry R, Ratner R et al. & LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind,

parallel treatment trial. Lancet 2009; 373: 473-481.

- Garber A, Henry R, Ratner R, et al, for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
- Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
- Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
- Garber A, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Program and abstracts of the American Diabetes Association (ADA) 69th Scientific Sessions. New Orleans, Louisiana, 5-9 June 2009.
- Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin-4) improves insulin sensitivity and (3-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076.
- Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRBSERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28: 2093-9.

- Gieason PP. Commentary: assessing step-therapy programs: a step in the right direction. *J Manag Care Pharm*. 2007; 13(3): 273-275.
- Goke B, Hershon K, Kerr D et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. *Horm Metab Res* 2008; 40: 892-895.
- Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE & Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007; 30: 1979-1987.
- Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? *Br J Pharmacol* 2009; 157: 1340-1351.
- Gutzwiller JP, Tschopp S, Bock A et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. *J Clin Endocrinol Metab* 2004; 89: 3055-3061.
- Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP & Sfitagliptin Study 014 Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. *Curr Med Res Opin* 2007; 23: 1329-1339.
- Hanefeld M, Schaper F, Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. *Cardiovasc Drugs Ther* 2008; 22: 225-31.
- Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widell MH, Brodows RG & GWAA Study Group. Exenatide versus insulin glargine in patients

with suboptimally controlled type 2 diabetes: a randomized . trial.
Ann Intern Med 2005; 143: 559-569.

- Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003; 20: 1016-21.
- Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-42.
- Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 405-14.
- Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepiride- versus glibenclamide induced hypoglycaemia. Eur J Clin Pharmacol 2003; 59: 91-7.
- International Diabetes Federation, Diabetes Atlas 2009; 4th Ed.
- International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334.
- Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res 2005; 15: 72-77.
- Kahn SE, Haffner SM, Heise MA et al. & ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
- Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med

2006; 355: 2427-43.

- Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 2008; 31: 845-51.
- Kapitza C, Flint A, Hindsberger C, Zdravkovic M. The effect of the once daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol. *Diabetes* 2008; 57(Suppl.1): A593.
- Kendall DM, Bhole D, Guan X et al. Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1C, and body weight in patients with type 2 diabetes mellitus (Abstract 784). *Diabetologia* 2006; 49(Suppl.1): 475.
- Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 2005; 28: 1083-1091.
- Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care*. 2005;28(5):1083-1091.
- Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Curr Med Res Opin* 2008; 24: 275-286.
- Knudsen LB, Madsen LW, Andersen S et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid c-cells causing calcitonin release and c-cell proliferation. *Endocrinology* 2010; 151: 1473-1486.
- Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of

glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. *J Med Chem* 2000; 43: 1664-1669. f Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. *Drugs* 2005; 65: 385-411.

- Krenfz AJ. Comparative safety of newer oral antidiabetic drugs. *Expert Opin Drug Saf* 2006; 5: 827-34.
- Krentz AJ. Comparative safety of newer oral antidiabetic drugs. *Expert Opin Drug Saf* 2006; 5: 827-34.
- Lebovitz HE. Oral therapies for diabetic hyperglycemia. *Endocrinol Metab Clin North Am* 2001; 30: 909-33.
- Lee DH, Lee IK, Jin SH, et al. Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. *Diabetes Care* 2007; 30(3): 622-8.
- Li J, Tian H, Li Q et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and doubledummy multicentre clinical trial. *Diabetes Obes Metab* 2007; 9: 558-65.
- MarijA, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved (3-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. *Horm Metab Res* 2006; 38: 838-844.
- Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed P-cell function in patients with type 2 diabetes and mild hyperglycemia. *J Clin Endocrinol*

Metab 2008; 93: 103-109.

- Marre M, Shaw J, Brandle M et al. & LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
- Matthews D, Marre M, Le-Thi TD, Zdravkovic M, Simon R. Liraglutide, a once-daily human GLP-1 analog, significantly improves β -cell function in subjects with type 2 diabetes. Program and abstracts of the American Diabetes Association (ADA) 68th Sessions. San Francisco, California, 6-10 June 2008.
- Matveyenko AV, Dry S, Cox HI et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009; 28: 1604-1615.
- May LD, Lefkowitz JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136: 449-52.
- Meyers RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007; 177: 723-4.
- Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group study. Clin Ther 2008; 30: 1448-1460.
- Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve

patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group study. Clin Ther 2008; 30: 1448-1460.

- Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2008;30:1448-1460.
- .
- Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic p-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
- Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-81.
- Nachnani JS, Bulchandani DG, Nookala A et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia2010;53: 153-159.
- Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
- Nathan DM, Buse JB, Davidson MB et al., American Diabetes I Association & European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus

statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32: 193-203.

- Nathan DM, Buse JB, Davidson MB et al., American Diabetes Association & European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32(1): 193-203.
- Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
- Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 2009;32(1):84-90.
- Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care. 2009;32(1):84-90.
- Nichols GA, Gomez-Camirero A. Weight changes following the

initiation of new anti-hyperglycaemic therapies. *Diabetes Obes Metab* 2007; 9: 96-102.

- Nichols GA, Gomez-Camirero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. *Diabetes Obes Metab* 2007; 9: 96-102.
- Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. *Circulation* 2004; 109: 962-965.
- Noel RA, Braun DK, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. *Pancreas* 2008; 37: 487.
- Novartis Europharm Limited. Jalra (vildagliptin) product information. Horsham, England: Novartis Europharm Limited, 2009. Available from URL:
http://www.emea.europa.eu/humandocs/PDFs/EPAR/jalra/emeacobine_d-/
- Noyan-Ashraf MH, Momen MA, Ban K et al." GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. *Diabetes* 2009; 58: 975-983.
- Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. *J Am Coll Cardiol* 2009; 53: S35-42.
- Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide—the FDA's review of a new antidiabetic therapy. *N Engl J Med* 2010; 362: 774-777.
- Pawlson LG, Lee TH. Clinical guidelines and performance measures. *Am J Manag Care*. 2010; 16(1): 16-17.

- Plutzjcy J, Garber AJ, Falahati A, Toft AD, Poulter NR. The once-daily! human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials. European Society of Cardiology Congress 2009. Barcelona, Spain, 29 August-2 September 2009.
- Pratley RE, Nauck M, Bailey T et al., for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
- Pratley RE, Nauck M, Bailey T, et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group", open-label trial. Lancet. 2010;375(9724): 1447-1456.
- Pratley RE, Nauck M, Bailey T, et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724): 1447-1456. j> Rajab A, Buss J, Diakoff E, Hadley GA, Osei K, Ferguson RM. Comparison of the portal vein and kidney subcapsule as sites for primate islet autotransplantation. Cell Transplant 2008; 17: 1015-1023.
- Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007; 27: 279-285.

- Raz I, Chen Y, Wu M et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr Med Res Opin* 2008; 24: 537-550.
- Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of P-cell function: a meta-analysis. *Am J Med Sci* 2009; 337: 321- 328.
- Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2008; 16: CD006739.
- Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract.* 2009;15:540-559.
- Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. *N Engl J Med* 2007; 357: 844-6.
- Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R, for the CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. *Curr Med Res Opin* 2009; 25: 2401-2411.
- Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R, for the CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. *Curr Med Res Opin* 2009; 25: 2401-2411.
- Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Care* 2007; 30: 217-223.

- Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug naïve patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2009; 11:571-578.
- Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drugnaive patients with type 2 diabetes. *Diabetes Obes Metab*. 2008;10(5):376-386.
- Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide versus insulin glargine in combination with metformin and sulfonylurea therapy in type 2 diabetes: a randomized controlled trial (LEAD-5 met+SU). *Diabetologia* 2009; 52: 2046-2055.
- Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. *Diabetologia*. 2009;52(10):2046-2055.
- Salas' M, Caro JJ. Are hypoglycaemia and other adverse effects similar among sulphonylureas? *Adverse Drug React Toxicol Rev* 2002;21:205-17.
- Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2006; 1: CD002967.
- Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. *Am J Med* 2008; 121: 149-57.
- Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-

blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535 - 42.

- Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes. Expert Opin Drug Saf2008;7:69-78.
- Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29: 759-764.
- Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA_{1c} over 1 year in drug-naïve patients with type 2 diabetes. DiabetMed 2007; 24: 955-961.
- Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA_{1c} over 1 year in drug-naïve patients with type 2 diabetes. DiabetMed 2007; 24: 955-961.
- Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011 Jan;13(1):55-64.
- Siegel D, Swislocki AL. Effects of antihypertensives on glucose metabolism. Metab Syndr Relat Disord. 2007;5:211-9.
- Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-1708.
- Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006; 63: 929-38.

- Stephan D, Winkler M, Ku"liner P, Russ U, Quast U. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. *Diabetologia* 2006; 49: 2039^18.
- Strack T. Metformin: a review. *Drugs Today (Bare)* 2008; 44: 303-14
- Tsilchorozidou T, Batterham RL, Conway GS. Metformin increases fasting plasma PYY in women with PCOS. *Clin Endocrinol* 2008; 69: 936-42.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352: 837-853.
- Utzsphneider KM, Tong J, Montgomery B et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves p-cell function and insulin sensitivity in subjects with impaired fasting glucose. *Diabetes Care* 2008; 31: 108-113.
- Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. *Cochrane Database Syst Rev* 2006; 4: CD005061..
- Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? *Diabetes Metab Res Rev.* 2011 Jan;27(l):3-13.
- Vella A, Bock G, Giesler PD et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. *Diabetes* 2007; 56: 1475— 1480.
- Vilsbll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-

stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. *Diabet Med* 2008; 25: 152-156.

- Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care*. 2007;30:1608-1610.
- Vollmer K, Gardiwal H, Menge BA, Goetze O, Deacon CF, Schmidt WE, Hoist JJ, Meier JJ (2009) Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. *J Clin Endocrinol Metab* 94:1379-1385
- Watson WA, Litovitz TL, Rodgers GC Jr et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. *Am J Emerg Med* 2005; 23: 589-666.
- Wellendorph P, Johansen LD, Brauner-Osborne H (2009) Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. *Mol Pharmacol* 76:453-465
- Williams B. The obese hypertensive: the weight of evidence against beta-blockers. *Circulation*. 2007;115:1973-4.
- Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data* from 10,246 patients with type 2 diabetes. *BMC Endocr Dis* 2010; 10: 7.
- Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. *BMC Endocr Dis* 2010; 10:7.

- Williams-Herman D, Seek TL, Golm G et al. Long-term efficacy with sitagliptin as monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. *Diabetes* 2009; 58(Suppl.1): A144-145.
- Yang j, Campitelli J, Hu G, Lin Y, Luo J, Xue C (2007) Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. *Life Sci* 81:272-279
- Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. *Diabetes Care* 2007; 30: 1574-6. I
- Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β -cell function in patients with type 2 diabetes. *Int J Clin Pract.* 2011 Feb;65(2): 154-64.
- Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. *Diabetes Care* 2005; 28: 2948-61.
- Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). *Diabetes Care* 2009; 32: 1224-1230.
- Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). *Diabetes Care* 2009; 32: 1224-1230.

- Zinnjan B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care*. 2009;32(7): 1224-1230
- Zinman B, Hoogwerf BJ, Dura' n Garci'a S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007; 146: 477-485.
- Zinman B, Hoogwerf BJ, Dura' n Garci'a S et al. The effect of adding xenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007; 146: 477-485.
- Zinman B, Hoogwerf BJ, Dura' n Garci'a S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007; 146: 477-485.